Onderneming Savara Inc Nyse
Aandelen
US5763141083
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Matthew Pauls
CEO | Chief Executive Officer | 53 | 27-04-17 |
David Lowrance
DFI | Director of Finance/CFO | 56 | 27-04-17 |
Robert M. Lutz
COO | Chief Operating Officer | 55 | 13-02-23 |
Raymond Pratt
CTO | Chief Tech/Sci/R&D Officer | 73 | 10-11-22 |
Anne Erickson
IRC | Investor Relations Contact | - | 01-10-18 |
Charles LaPree
LAW | General Counsel | - | 01-08-21 |
Kate McCabe
LAW | General Counsel | - | 01-03-18 |
Scott Wilhoit
PRN | Corporate Officer/Principal | 61 | 09-01-23 |
Peter M. Clarke
PRN | Corporate Officer/Principal | 64 | 01-09-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Ramsay
BRD | Director/Board Member | 59 | 27-04-17 |
Richard Hawkins
BRD | Director/Board Member | 75 | 01-10-10 |
Nevan Elam
BRD | Director/Board Member | 56 | 01-02-09 |
Ricky Sun
BRD | Director/Board Member | 50 | 24-12-19 |
Joseph McCracken
BRD | Director/Board Member | 71 | 27-04-17 |
Matthew Pauls
CEO | Chief Executive Officer | 53 | 27-04-17 |
Director/Board Member | 64 | 03-12-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 138 188 891 | 130 399 382 ( 94,36 %) | 0 | 94,36 % |
Bedrijfsgegevens
Savara, Inc.
1717 Langhorne Newtown Road Suite 302
19047, Langhorne
+(512) 614-1848
http://www.savarapharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |
- Beurs
- Aandelen
- Koers SVRA
- Koers
- Onderneming Savara Inc